JACKSON, MI – Henry Ford Allegiance Health is advancing radiation treatment for cancer patients in south central Michigan and beyond with the Varian Ethos™ therapy system. Driven by artificial intelligence technology, the system provides a real-time view of a patient’s anatomy and allows the radiation dosage to be adapted in real time to continuous variations in the shape and positioning of the individual’s tumor and normal tissues. Ethos is an advanced software update to the state-of the-art Halcyon linear accelerator, which Henry Ford Allegiance Health was the first in Michigan to use in December 2019. The personalized targeting capability of Ethos helps improve overall outcomes and reduces radiation exposure to healthy tissue.
“We are the first hospital in Michigan and the fifth in the United States to offer the combined Halcyon technology and Ethos adaptive therapy, which increases the capability, flexibility and efficiency of radiation treatment. It delivers radiation doses more quickly while enhancing precision and safety,” said Annette Kretzler, M.D., Medical Director Henry Ford Allegiance Radiation Oncology. A radiation treatment session, including the adaptive Ethos option, typically takes just 15 minutes.
“Henry Ford Allegiance Health is on the leading edge of radiation treatment. Adaptive radiation therapy transforms our ability to fight cancer by personalizing radiation treatments in real time according to changes in each patient’s anatomy and internal organ motion,” said Benjamin Movsas, M.D., Interim Medical Director of Henry Ford Cancer Institute and Chair of its Radiation Oncology Department. “With the addition of this new technology, the Henry Ford Cancer Institute is honored to be one of the only cancer centers in the world to perform both MR-guided adaptive treatment and CT-guided adaptive treatment.”
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
Henry Ford Allegiance Health plans to establish clinical research to maximize the full potential of this groundbreaking technology.
The combined Halcyon and Ethos system was designed around the particular needs of patients with cancer. Shorter treatment times, combined with the equipment’s comfortable treatment bed, smooth and quiet motion, and soft lighting, contribute to a more relaxing patient experience.
“The acquisition of Ethos and Halcyon reflects Henry Ford Allegiance Health’s commitment to invest in the communities we serve by bringing local access to the best, safest and most personalized cancer care technology available,” said Paula Autry, President and CEO, Henry Ford Allegiance Health and Senior Vice President and CEO, Central Market, Henry Ford Health System.